Skip to main content

Anika Therapeutics(ANIK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine

Globe Newswire - Wed Jul 27, 2022

BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaedic Society for Sports Medicine (AOSSM) for Tactoset® Injectable Bone Substitute for hardware augmentation. This award highlights the innovative nature of Tactoset, a calcium phosphate based, biocompatible bone graft substitute that incorporates Anika’s core hyaluronic acid (HA) technology, and its use to augment hardware and support bone fragments during surgical procedures. The HA component of Tactoset makes the product highly flowable, easily injectable and able to interdigitate trabecular bone architecture, such as insufficiency fractures, with overall improved handling characteristics compared to competitive products.  

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Short sales on the TSX: What bearish investors are betting against
Larry MacDonald